Life Sciences Mergers and Acquisitions

Evaluating, Negotiating, and Consummating Successful Deals

Wednesday, March 14, 2007

About

Close the deal - Ensure successful and profitable life sciences mergers and acquisitions

In the past year, the life sciences industry has seen a marked increase in M&A activity. Life sciences companies have already spent billions of dollars on these deals. Due to the increased price and complexity of collaborations, many life sciences companies are now turning to M&As as either an exit strategy or a way to grow their business.

Effectively predict and manage the specific challenges of life sciences M&As

Negotiating M&As in the life sciences arena is significantly different from deals in other industries. For life sciences companies, you need to know how to handle the unique challenges in valuing and conducting an accurate due diligence on a pipeline. In addition, there are specific regulatory and antitrust concerns that arise in life sciences companies that must be considered with an M&A, as well as distinctive representations and warranties in your deal.

Understand the nuts and bolts of M&A deals

For any M&A deal, there are a number of factors that need to be addressed. Before beginning any M&A, the company needs to consider the business reasons for entering into the transaction as well as the best structure for the deal. Ensuring a workable post integration process is also essential to a successful deal.

Contents & Contributors

About

Close the deal - Ensure successful and profitable life sciences mergers and acquisitions

In the past year, the life sciences industry has seen a marked increase in M&A activity. Life sciences companies have already spent billions of dollars on these deals. Due to the increased price and complexity of collaborations, many life sciences companies are now turning to M&As as either an exit strategy or a way to grow their business.

Effectively predict and manage the specific challenges of life sciences M&As

Negotiating M&As in the life sciences arena is significantly different from deals in other industries. For life sciences companies, you need to know how to handle the unique challenges in valuing and conducting an accurate due diligence on a pipeline. In addition, there are specific regulatory and antitrust concerns that arise in life sciences companies that must be considered with an M&A, as well as distinctive representations and warranties in your deal.

Understand the nuts and bolts of M&A deals

For any M&A deal, there are a number of factors that need to be addressed. Before beginning any M&A, the company needs to consider the business reasons for entering into the transaction as well as the best structure for the deal. Ensuring a workable post integration process is also essential to a successful deal.

Contents & Contributors


VIEW FROM THE BENCH
Benjamin Barnett, Dechert LLP (Philadelphia, PA)
Honorable Robert B. Collings, District of Massachusetts
Honorable Andrew J. Peck, Southern District of New York

AN EXPENSIVE BLUDGEON: PLAINTIFFS' REQUESTS FOR DEFENDANTS' DATABASES
Mark Yacano, Wright Robinson Osthimer & Tatum, (Alexandria, VA)

ENSURING LITIGATION READINESS-GOING BEYOND THE STANDARD ZUBULAKE ANALYSIS TO MEET THE DEMANDS OF THE LIFE SCIENCES INDUSTRY
Mary Mack, Fios Inc. (Portland, OR)
Janet Kwuon, Reed Smith, LLP (Los Angeles, CA)
Michael Harrington, Eli Lilly and Company (Indianapolis, IN)
Andrea Johnson, Powers & Frost (Houston, TX)

MANAGING VOLUMINOUS DATABASES OF ADVERSE EVENT REPORTS, MARKETING COMMUNICATIONS, AND RELATED DOCUMENTS
Curtis Oltmans, Novo Nordisk (Princeton, NJ)

E-DISCOVERY MANAGING DATABASES, MARKETING COMMUNICATIONS AND RELATED DOCUMENTS
Laurie Weiss, Fulbright & Jaworski (Houston, TX)

IMPLEMENTING NEW TECHNOLOGIES IN THE TRENCHES
Ginger Heyman Pigott, Reed Smith LLP (Los Angeles, CA)
George Tsioros, KPMG Forensic (New York, NY)

AVOIDING THE DANGERS OF 21ST CENTURY ELECTRONIC COMMUNICATIONS
Brian Conway, Eisai Pharmaceuticals(Teaneck, NJ)
Lana Varney, Fulbright & Jaworski, (Austin, TX)

GAINING CONTROL OVER THE MESSAGES SALES REPS PUT OUT
Perry Goldman, Elan Pharmaceuticals, Inc. (San Francisco, CA)
John P. Lavelle, Jr., Ballard Spahr Andrews & Ingersoll, (Philadelphia, PA)

PROTECTING THE COMPANY'S INTERESTS DURING DOCUMENT PRODUCTION
Sean P. Wajert, Dechert LLP (Philadelphia, PA)

MANAGING AND CONTROLLING E-DISCOVERY COSTS
Stephen A. Wood, Kelley Drye & Warren LLP (Chicago IL)

MANAGING AND CONTROLLING E-DISCOVERY COSTS
Jennifer Liebman, LexisNexis Applied Discovery (Philadelphia, PA)

MAINTAINING PRIVACY AND DATA SECURITY IN AN ELECTRONIC ENVIRONMENT
Alan Winchester, Harris Beach (New York, NY)
Owen O'Connor, Elan Pharmaceuticals (London, UK)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0